Parkinson disease

Diffusion MR imaging to detect nigrostriatal pathway loss in a marmoset model treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Keigo Hikishima, Kiyoshi Ando, Ryutaro Yano, Kenji Kawai, Yuji Komaki, Takashi Inoue, Toshio Itoh, Masayuki Yamada, Suketaka Momoshima, Hirotaka J. Okano, Hideyuki Okano

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Purpose: To investigate the use of diffusion-tensor imaging (DTI) to detect denervation of the nigrostriatal pathway in a nonhuman primate model of Parkinson disease (PD) after treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Materials and Methods: This study was approved by the institutional committee for animal experiments. DTI was performed in marmosets (n = 6) by using a 7-T magnetic resonance (MR) imager before and 10 weeks after administration of MPTP. Fixed brains of a normal marmoset and a marmoset model of PD (n = 1) were analyzed by using microscopic tractography. Tyrosine-hydroxylase staining of dopaminergic neurons and three-dimensional histologic analysis also were performed in normal marmosets (n = 2) and a PD marmoset model (n = 2) to validate the course of the nigrostriatal pathway revealed at tractography. Statistical analysis of voxel-based and post hoc region-of-interest analyses of DTI maps was performed by using a paired t test. Results: At voxel-based analysis of DTI before and after treatment, MPTP-treated marmoset brains showed significantly increased axial and radial diffusivity in the bilateral nigrostriatal pathway (P < .05, false discovery rate corrected). The largest area of significantly increased diffusivity was an area of axial diffusivity in the right hemispere (177 mm3) that corresponded to the location of dopaminergic neurodegeneration at histologic evaluation. Region-of-interest analysis revealed a 27% increase in axial diffusivity in the right hemisphere (1.198 mm2/sec ± 0.111 to 1.522 mm2/sec ± 0.118; P = .002). Three-dimensional histologic analysis with tyrosine-hydroxylase staining showed the course of the nigrostriatal pathway and degeneration in the PD marmoset model as the absence of a tyrosinehydroxylase stained region. Microscopic tractography showed that the connection of the substantia nigra to the striatum followed the same course as the nigrostriatal pathway and fewer fiber tracts in the PD marmoset model. Conclusion: DTI and microscopic tractography showed the loss of fiber structures of the nigrostriatal pathway in the marmoset model of PD. The results of this study provide a potential basis for the use of DTI in the clinical diagnosis of PD.

Original languageEnglish
Pages (from-to)430-437
Number of pages8
JournalRadiology
Volume275
Issue number2
DOIs
Publication statusPublished - 01-05-2015

Fingerprint

Callithrix
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Diffusion Magnetic Resonance Imaging
Parkinson Disease
Diffusion Tensor Imaging
Tyrosine 3-Monooxygenase
Staining and Labeling
Dopaminergic Neurons
Brain
Denervation
Substantia Nigra
Primates
Magnetic Resonance Spectroscopy

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

Hikishima, Keigo ; Ando, Kiyoshi ; Yano, Ryutaro ; Kawai, Kenji ; Komaki, Yuji ; Inoue, Takashi ; Itoh, Toshio ; Yamada, Masayuki ; Momoshima, Suketaka ; Okano, Hirotaka J. ; Okano, Hideyuki. / Parkinson disease : Diffusion MR imaging to detect nigrostriatal pathway loss in a marmoset model treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. In: Radiology. 2015 ; Vol. 275, No. 2. pp. 430-437.
@article{60c927c0bbf0427596f90cc776a58f97,
title = "Parkinson disease: Diffusion MR imaging to detect nigrostriatal pathway loss in a marmoset model treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",
abstract = "Purpose: To investigate the use of diffusion-tensor imaging (DTI) to detect denervation of the nigrostriatal pathway in a nonhuman primate model of Parkinson disease (PD) after treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Materials and Methods: This study was approved by the institutional committee for animal experiments. DTI was performed in marmosets (n = 6) by using a 7-T magnetic resonance (MR) imager before and 10 weeks after administration of MPTP. Fixed brains of a normal marmoset and a marmoset model of PD (n = 1) were analyzed by using microscopic tractography. Tyrosine-hydroxylase staining of dopaminergic neurons and three-dimensional histologic analysis also were performed in normal marmosets (n = 2) and a PD marmoset model (n = 2) to validate the course of the nigrostriatal pathway revealed at tractography. Statistical analysis of voxel-based and post hoc region-of-interest analyses of DTI maps was performed by using a paired t test. Results: At voxel-based analysis of DTI before and after treatment, MPTP-treated marmoset brains showed significantly increased axial and radial diffusivity in the bilateral nigrostriatal pathway (P < .05, false discovery rate corrected). The largest area of significantly increased diffusivity was an area of axial diffusivity in the right hemispere (177 mm3) that corresponded to the location of dopaminergic neurodegeneration at histologic evaluation. Region-of-interest analysis revealed a 27{\%} increase in axial diffusivity in the right hemisphere (1.198 mm2/sec ± 0.111 to 1.522 mm2/sec ± 0.118; P = .002). Three-dimensional histologic analysis with tyrosine-hydroxylase staining showed the course of the nigrostriatal pathway and degeneration in the PD marmoset model as the absence of a tyrosinehydroxylase stained region. Microscopic tractography showed that the connection of the substantia nigra to the striatum followed the same course as the nigrostriatal pathway and fewer fiber tracts in the PD marmoset model. Conclusion: DTI and microscopic tractography showed the loss of fiber structures of the nigrostriatal pathway in the marmoset model of PD. The results of this study provide a potential basis for the use of DTI in the clinical diagnosis of PD.",
author = "Keigo Hikishima and Kiyoshi Ando and Ryutaro Yano and Kenji Kawai and Yuji Komaki and Takashi Inoue and Toshio Itoh and Masayuki Yamada and Suketaka Momoshima and Okano, {Hirotaka J.} and Hideyuki Okano",
year = "2015",
month = "5",
day = "1",
doi = "10.1148/radiol.14140601",
language = "English",
volume = "275",
pages = "430--437",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "2",

}

Hikishima, K, Ando, K, Yano, R, Kawai, K, Komaki, Y, Inoue, T, Itoh, T, Yamada, M, Momoshima, S, Okano, HJ & Okano, H 2015, 'Parkinson disease: Diffusion MR imaging to detect nigrostriatal pathway loss in a marmoset model treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', Radiology, vol. 275, no. 2, pp. 430-437. https://doi.org/10.1148/radiol.14140601

Parkinson disease : Diffusion MR imaging to detect nigrostriatal pathway loss in a marmoset model treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. / Hikishima, Keigo; Ando, Kiyoshi; Yano, Ryutaro; Kawai, Kenji; Komaki, Yuji; Inoue, Takashi; Itoh, Toshio; Yamada, Masayuki; Momoshima, Suketaka; Okano, Hirotaka J.; Okano, Hideyuki.

In: Radiology, Vol. 275, No. 2, 01.05.2015, p. 430-437.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Parkinson disease

T2 - Diffusion MR imaging to detect nigrostriatal pathway loss in a marmoset model treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

AU - Hikishima, Keigo

AU - Ando, Kiyoshi

AU - Yano, Ryutaro

AU - Kawai, Kenji

AU - Komaki, Yuji

AU - Inoue, Takashi

AU - Itoh, Toshio

AU - Yamada, Masayuki

AU - Momoshima, Suketaka

AU - Okano, Hirotaka J.

AU - Okano, Hideyuki

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Purpose: To investigate the use of diffusion-tensor imaging (DTI) to detect denervation of the nigrostriatal pathway in a nonhuman primate model of Parkinson disease (PD) after treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Materials and Methods: This study was approved by the institutional committee for animal experiments. DTI was performed in marmosets (n = 6) by using a 7-T magnetic resonance (MR) imager before and 10 weeks after administration of MPTP. Fixed brains of a normal marmoset and a marmoset model of PD (n = 1) were analyzed by using microscopic tractography. Tyrosine-hydroxylase staining of dopaminergic neurons and three-dimensional histologic analysis also were performed in normal marmosets (n = 2) and a PD marmoset model (n = 2) to validate the course of the nigrostriatal pathway revealed at tractography. Statistical analysis of voxel-based and post hoc region-of-interest analyses of DTI maps was performed by using a paired t test. Results: At voxel-based analysis of DTI before and after treatment, MPTP-treated marmoset brains showed significantly increased axial and radial diffusivity in the bilateral nigrostriatal pathway (P < .05, false discovery rate corrected). The largest area of significantly increased diffusivity was an area of axial diffusivity in the right hemispere (177 mm3) that corresponded to the location of dopaminergic neurodegeneration at histologic evaluation. Region-of-interest analysis revealed a 27% increase in axial diffusivity in the right hemisphere (1.198 mm2/sec ± 0.111 to 1.522 mm2/sec ± 0.118; P = .002). Three-dimensional histologic analysis with tyrosine-hydroxylase staining showed the course of the nigrostriatal pathway and degeneration in the PD marmoset model as the absence of a tyrosinehydroxylase stained region. Microscopic tractography showed that the connection of the substantia nigra to the striatum followed the same course as the nigrostriatal pathway and fewer fiber tracts in the PD marmoset model. Conclusion: DTI and microscopic tractography showed the loss of fiber structures of the nigrostriatal pathway in the marmoset model of PD. The results of this study provide a potential basis for the use of DTI in the clinical diagnosis of PD.

AB - Purpose: To investigate the use of diffusion-tensor imaging (DTI) to detect denervation of the nigrostriatal pathway in a nonhuman primate model of Parkinson disease (PD) after treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Materials and Methods: This study was approved by the institutional committee for animal experiments. DTI was performed in marmosets (n = 6) by using a 7-T magnetic resonance (MR) imager before and 10 weeks after administration of MPTP. Fixed brains of a normal marmoset and a marmoset model of PD (n = 1) were analyzed by using microscopic tractography. Tyrosine-hydroxylase staining of dopaminergic neurons and three-dimensional histologic analysis also were performed in normal marmosets (n = 2) and a PD marmoset model (n = 2) to validate the course of the nigrostriatal pathway revealed at tractography. Statistical analysis of voxel-based and post hoc region-of-interest analyses of DTI maps was performed by using a paired t test. Results: At voxel-based analysis of DTI before and after treatment, MPTP-treated marmoset brains showed significantly increased axial and radial diffusivity in the bilateral nigrostriatal pathway (P < .05, false discovery rate corrected). The largest area of significantly increased diffusivity was an area of axial diffusivity in the right hemispere (177 mm3) that corresponded to the location of dopaminergic neurodegeneration at histologic evaluation. Region-of-interest analysis revealed a 27% increase in axial diffusivity in the right hemisphere (1.198 mm2/sec ± 0.111 to 1.522 mm2/sec ± 0.118; P = .002). Three-dimensional histologic analysis with tyrosine-hydroxylase staining showed the course of the nigrostriatal pathway and degeneration in the PD marmoset model as the absence of a tyrosinehydroxylase stained region. Microscopic tractography showed that the connection of the substantia nigra to the striatum followed the same course as the nigrostriatal pathway and fewer fiber tracts in the PD marmoset model. Conclusion: DTI and microscopic tractography showed the loss of fiber structures of the nigrostriatal pathway in the marmoset model of PD. The results of this study provide a potential basis for the use of DTI in the clinical diagnosis of PD.

UR - http://www.scopus.com/inward/record.url?scp=84929017889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929017889&partnerID=8YFLogxK

U2 - 10.1148/radiol.14140601

DO - 10.1148/radiol.14140601

M3 - Article

VL - 275

SP - 430

EP - 437

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 2

ER -